Research programme: metformin/atypical antipsychotic - BTG

Drug Profile

Research programme: metformin/atypical antipsychotic - BTG

Alternative Names: Metformin/atypical antipsychotic

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BTG
  • Class Biguanides
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity(Combination therapy) in United Kingdom (PO)
  • 01 Jun 2007 Preclinical trials in Obesity in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top